Sheffield Teaching Hospitals NHS Foundation Trust — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications3liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ALS-CarE — A Programme for Amyotrophic Lateral Sclerosis Care in EuropeDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	Traitement symptomatique	United Kingdom	À vérifier
ALS-CarE — A Programme for Amyotrophic Lateral Sclerosis Care in EuropeDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	Traitement symptomatique	United Kingdom	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
ALS-CarE — A Programme for Amyotrophic Lateral Sclerosis Care in Europe	Sclérose latérale amyotrophique	À vérifier	NCT03081338	ALS-CarE — A Programme for Amyotrophic Lateral Sclerosis Care in Europe	UNKNOWN

Publications

3

Molécule	Indication / population	Titre	Journal	Date
ALS-CarE — A Programme for Amyotrophic Lateral Sclerosis Care in Europe		Telehealth approach for amyotrophic lateral sclerosis patients: the experience during COVID-19 pandemic.	Acta neurologica Scandinavica
ALS-CarE — A Programme for Amyotrophic Lateral Sclerosis Care in Europe		Prognostic communication in amyotrophic lateral sclerosis: findings from a Nationwide Italian survey.	Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ALS-CarE — A Programme for Amyotrophic Lateral Sclerosis Care in Europe		Frequency and Early Predictors of Cognitive Deterioration in Amyotrophic Lateral Sclerosis: A Longitudinal Population-Based Study.	Annals of neurology